A Real-world Efficacy and Safety Study of Amlotinib for HER2-negative Advanced Breast Cancer
NCT06340165
·
clinicaltrials.gov ↗
UNKNOWN
Status
153
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
Anlotinib
Sponsor
The First Hospital of Jilin University